Drug | Trade (brand) name | Concentration of elemental iron | Dosing (adults) | Test dose | Premedication |
Ferric carboxymaltose (FCM)* | Injectafer (United States), Ferinject (United Kingdom and other countries) | 50 mg/mL |
or
| Not required |
|
Ferric derisomaltose (previously called iron isomaltoside) | Monoferric (United States, Canada), Monofer (United Kingdom, other countries) | 100 mg/mL |
or
or
| Not required | |
Ferric gluconate (FG) | Ferrlecit | 12.5 mg/mL |
| Not required, but recommended if the patient has a history of multiple drug allergies | |
Ferumoxytol¶ | Feraheme (United States), Rienso (United Kingdom and other countries) | 30 mg/mL |
or
| Not required | |
Iron dextran, low molecular weight (LMW ID)Δ | INFeD (United States), Dexiron (Canada), CosmoFer (United Kingdom and other countries) | 50 mg/mL |
or
| Yes, 25 mg (0.5 mL) prior to the first dose | |
Iron sucrose (IS) | Venofer | 20 mg/mL |
| Not required, but recommended if the patient has a history of multiple drug allergies |
* Ferric carboxymaltose can cause hypophosphatemia and should be avoided in individuals with hypophophatemia or at increased risk. Monitoring of serum phosphate is needed in individuals receiving more than one dose.
¶ Notify radiologist if patient has a magnetic resonance imaging (MRI) scan, including noncontrast scanning, within 3 months of ferumoxytol administration, as the properties of ferumoxytol affect the appearance of different imaging sequences.
Δ High molecular weight iron dextran (HMW ID) is no longer available.Do you want to add Medilib to your home screen?